Jeffrey S Adams

US Patent:

8314151, Nov 20, 2012

Filed:

Aug 31, 2009

Appl. No.:

12/584131

Inventors:

Sarah Spiegel - Richmond VA, US
Robert Elliot Zipkin - Wynnewood PA, US
Jeffrey Kroll Adams - Fort Washington PA, US

Assignee:

Enzo Therapeutics, Inc. - Farmingdale NY

International Classification:

A61K 31/133

US Classification:

514653, 514649, 514646, 514579, 564355, 564336, 564305

Abstract:

Provided are novel compositions and analogs which are useful in a number of applications, indications and diseases, as well as for monitoring pharmakinetics and patient management. These compounds and analogs are applicable to treating tumors of the central nervous system, e. g. , glioblastoma (GBM).

US Patent:

8372888, Feb 12, 2013

Filed:

Apr 29, 2009

Appl. No.:

12/387228

Inventors:

Robert E. Zipkin - Wynnewood PA, US
Sarah Spiegel - Richmond VA, US
Jeffrey Kroll Adams - Fort Washington PA, US

Assignee:

Enzo Therapeutics, Inc. - Farmingdale NY

International Classification:

A61K 31/133

US Classification:

514653, 514649, 514646, 514579, 564355, 564336, 564305

Abstract:

Provided are novel compositions which uniquely inhibit sphingosine kinase Type 1 (SphK1) and which are useful in a number of applications including killing or damaging cancer cells, inducing apoptosis, inhibiting growth, metastasis and development of chemoresistance in cancer cells, leukemia, increasing the effectiveness of anti-cancer agents, attenuating immune reactivity, inhibiting survival signaling in cancer cells, and reducing symptoms of multiple sclerosis.

US Patent:

20130245321, Sep 19, 2013

Filed:

Oct 11, 2012

Appl. No.:

13/649221

Inventors:

SARAH SPIEGEL - RICHMOND VA, US
ROBERT ELLIOT ZIPKIN - WYNNEWOOD PA, US
JEFFREY KROLL ADAMS - FORT WASHINGTON PA, US

International Classification:

C07C 215/28
C07C 233/18
C07C 217/64

US Classification:

564219, 564360

Abstract:

Provided are novel compositions and analogs which are useful in a number of applications, indications and diseases, as well as for monitoring pharmakinetics and patient management. These compounds and analogs are applicable to treating tumors of the central nervous system, e.g., glioblastoma (GBM).

US Patent:

20210302445, Sep 30, 2021

Filed:

Apr 14, 2021

Appl. No.:

17/229939

Inventors:

- Farmingdale NY, US
ROBERT ELLIOT ZIPKIN - WYNNEWOOD PA, US
JEFFREY KROLL ADAMS - FORT WASHINGTON PA, US
WAYNE FORREST PATTON - DIX HILLS NY, US
JAMES J. DONEGAN - AMESBURY MA, US

Assignee:

ENZO LIFE SCIENCES, INC. - Farmingdale NY

International Classification:

G01N 33/92
C07J 9/00
C07J 43/00
C07K 16/44
G01N 33/569
G01N 33/53
C07K 16/18

Abstract:

Provided is an antibody composition comprising antibodies that specifically bind to 22-hydroxycholesterol, 24S-hydroxycholesterol, 25-hydroxycholesterol, 26-hydroxycholesterol or 27-hydroxycholesterol. Also provided is a method of making antibodies that specifically bind to 22-hydroxycholesterol, 24S-hydroxycholesterol, 25-hydroxycholesterol, 26-hydroxycholesterol or 27-hydroxycholesterol is provided. Further provided is a method of assaying for 22-hydroxycholesterol, 24S-hydroxycholesterol, 25-hydroxycholesterol, 26-hydroxycholesterol or 27-hydroxycholesterol is provided. Still further provided is a kit for detecting 22-hydroxycholesterol, 24S-hydroxycholesterol, 25-hydroxycholesterol, 26-hydroxycholesterol or 27-hydroxycholesterol.

US Patent:

20200197328, Jun 25, 2020

Filed:

Mar 10, 2020

Appl. No.:

16/813961

Inventors:

- Farmingdale NY, US
- Richmond VA, US
Jeffrey Kroll Adams - Fort Washington PA, US

Assignee:

Enzo Therapeutics, Inc. - Farmingdale NY
Virginia Commonwealth University - Richmond VA

International Classification:

A61K 31/135
C07C 233/18
C07C 217/64
C07C 215/28
C07D 295/092
C07D 263/06
C07C 323/32
A61K 31/40
A61P 11/06

Abstract:

Provided are inhibitors of sphingosine kinase Type I that are useful in a number of applications, indications and diseases, as well as for monitoring pharmacokinetics and patient management. These compounds are applicable to treating ischemic diseases such as myocardial infarction and stroke.

US Patent:

20200069611, Mar 5, 2020

Filed:

Sep 17, 2019

Appl. No.:

16/572699

Inventors:

- Farmingdale NY, US
- Richmond VA, US
Jeffrey Kroll Adams - Fort Washington PA, US

Assignee:

Enzo Therapeutics, Inc. c/o Enzo Biochem, Inc. - Farmingdale NY
Virginia Commonwealth University - Richmond VA

International Classification:

A61K 31/135
C07C 233/18
C07C 217/64
C07C 215/28
C07D 295/092
C07D 263/06
C07C 323/32
A61K 31/40
A61P 11/06

Abstract:

Provided are inhibitors of sphingosine kinase Type I that are useful in a number of applications, indications and diseases, as well as for monitoring pharmacokinetics and patient management. These compounds are applicable to treating tumors of the central nervous system, such as glioblastoma multiforme (GBM).

US Patent:

20190383839, Dec 19, 2019

Filed:

Dec 19, 2018

Appl. No.:

16/225868

Inventors:

- NEW YORK NY, US
ROBERT ELLIOT ZIPKIN - WYNNEWOOD PA, US
JEFFREY KROLL ADAMS - FORT WASHINGTON PA, US
WAYNE FORREST PATTON - DIX HILLS NY, US
JAMES J. DONEGAN - LONG BEACH NY, US

Assignee:

ENZO LIFE SCIENCES, INC. C/0 ENZO BIOCHEM, INC. - NEW YORK NY

International Classification:

G01N 33/92
C07J 9/00
C07J 43/00
C07K 16/44
G01N 33/569
G01N 33/53
C07K 16/18

Abstract:

Provided is a derivative of 22-hydroxycholesterol, 24S-hydroxycholesterol, 25-hydroxycholesterol, 26-hydroxycholesterol or 27-hydroxycholesterol. Also provided is a protein conjugated to the above derivative. Further provided is an antibody composition comprising antibodies that specifically bind to 22-hydroxycholesterol, 24S-hydroxycholesterol, 25-hydroxycholesterol, 26-hydroxycholesterol or 27-hydroxycholesterol. Additionally, a method of making antibodies that specifically bind to 22-hydroxycholesterol, 24S-hydroxycholesterol, 25-hydroxycholesterol, 26-hydroxycholesterol or 27-hydroxycholesterol is provided. Also, a method of assaying for 22-hydroxycholesterol, 24S-hydroxycholesterol, 25-hydroxycholesterol, 26-hydroxycholesterol or 27-hydroxycholesterol is provided. Additionally provided is a kit for detecting 22-hydroxycholesterol, 24S-hydroxycholesterol, 25-hydroxycholesterol, 26-hydroxycholesterol or 27-hydroxycholesterol. A method of detecting an enzyme or enzymes utilized in phase II drug metabolism is also provided. Also, a method of detecting an enzyme that synthesizes 22-hydroxycholesterol, 24S-hydroxycholesterol, 25-hydroxycholesterol, 26-hydroxycholesterol or 27-hydroxycholesterol is provided. Further provided is a method of evaluating progression of multiple sclerosis in a patient. Also provided is a method of determining whether a treatment for multiple sclerosis in a patient is effective. Further, a method of evaluating progression of Huntington's disease in a patient is provided. Additionally provided is a method of determining whether a treatment for Huntington's disease in a patient is effective.

US Patent:

20190111007, Apr 18, 2019

Filed:

Nov 26, 2018

Appl. No.:

16/199337

Inventors:

- Farmingdale NY, US
- Richmond VA, US
Jeffrey Kroll Adams - Fort Washington PA, US

Assignee:

Enzo Therapeutics, Inc. c/o Enzo Biochem, Inc. - Farmingdale NY
Virginia Commonwealth University - Richmond VA

International Classification:

A61K 31/135
C07C 233/18
C07C 217/64
C07D 295/092
C07C 215/28
C07C 323/32
A61K 31/40
C07D 263/06

Abstract:

Provided are inhibitors of sphingosine kinase Type I and their use in the treatment of asthma, among other indications and diseases.